Seagen

Youtube Subscribe

Open: 193.69 Close: 193.47 Change: -0.22

How to get informed about Seagen Company Inc quickly using an AI.

The game is changing. There is a new strategy to evaluate Seagen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Seagen are: Seagen, market, Inc, share, report, price, net, and the …

Concept Map

Semantic Network

Stock Summary

Seagen Inc. develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors. It has collaboration agreements with Takeda.

Today's Summary

Pfizer expects Seagen deal to close in late 2023 or early 2024. Pfizer expected to generate about $2.2 bln of revenue. Seagen is headquartered in Seattle, Washington area.

Today's News

Seagen - Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum. Seagen Inc. reported record net product sales, with significant year-over-year growth of 26 percent. Pfizer expects Seagen deal to close in late 2023 or early 2024. Seagen expects to generate about $2.2 bln of revenue. As of June 30, 2023, Seagen had $1.3 billion in cash and investments. The employee data is based on information from people who have self-reported their past or current employments at Seagen. None of the information on this page has been provided or approved by Seagen. The data does not represent the view of Seagen and its employees. Seagen Inc. faces EPS Estimate Downgrade, Raises Concerns for Q2 2023 and Beyond. Investors should keep an eye on Seagen as it navigates through this dynamic market environment. Seagen stock price today (nasdaq: sgen) quote, market cap, chart, chart | wallstreetzen.com. Seagen Inc. and changed its name to Seagen. Seagens stock price per share is $193.47 per share. Stifel Nicolaus increased their price target on shares of Seagen from $157.00 to $229.00 in a research report on Friday, April 28th. StockNews.com assumed coverage on Seagen in a report on Sunday. Seagen Inc. (SGEN) has a market cap or net worth of $36.28 billion. Seagen has 187.50 million shares outstanding. The company had revenue of $2.16 billion, last 12 months. The market volatility has been lower than the market average. Morgan Stanley reiterates Seagen (sgen) equal-weight recommendation. Analyst Price Forecast Suggests 18.52% Upside. Seagen is headquartered in Seattle, Washington area.

Stock Profile

"Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington."

Keywords

Are looking for the most relevant information about Seagen? Investor spend a lot of time searching for information to make investment decisions in Seagen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Seagen are: Seagen, market, Inc, share, report, price, net, and the most common words in the summary are: seagen, stock, market, job, price, inc, news, . One of the sentences in the summary was: Pfizer expects Seagen deal to close in late 2023 or early 2024. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #seagen #stock #market #job #price #inc #news.

Read more →

Youtube Subscribe

---